Fractyl Health, Inc. (NASDAQ:GUTS) shares are trading lower. The company announced new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform.
What To Know: The data, shared during the American Diabetes Association's 85th Scientific Sessions, showed that a single dose of Rejuva prevented weight gain and high blood sugar in mice on a high-fat diet. In one group, Rejuva reduced body weight by 20% and lowered blood glucose by 38% within 21 days. These effects were maintained through the 37-day study period despite continued high-fat diet exposure.
